INS and Insulin resistance: Firstly, SCFAs act on terminal L cells in the small intestine, prompting them to release GLP-1, enhancing glucose-dependent insulin secretion and improving insulin resistance, which reduces appetite and delays gastric emptying, and contributes to the reduction of body weight and body fat, which are the main factors in the formation of MASLD.